PTC Therapeutics Inc. (PTCT)
NASDAQ: PTCT
· Real-Time Price · USD
65.37
2.35 (3.73%)
At close: Oct 03, 2025, 3:59 PM
66.30
1.42%
After-hours: Oct 03, 2025, 07:27 PM EDT
3.73% (1D)
| Bid | 64.8 |
| Market Cap | 5.19B |
| Revenue (ttm) | 1.76B |
| Net Income (ttm) | 629.17M |
| EPS (ttm) | 7.12 |
| PE Ratio (ttm) | 9.18 |
| Forward PE | -22.27 |
| Analyst | Buy |
| Dividends | n/a |
| Ask | 69.78 |
| Volume | 2,676,071 |
| Avg. Volume (20D) | 1,261,800 |
| Open | 63.29 |
| Previous Close | 63.02 |
| Day's Range | 63.29 - 67.40 |
| 52-Week Range | 34.57 - 67.40 |
| Beta | 0.55 |
| Ex-Dividend Date | n/a |
About PTCT
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol PTCT
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for PTCT stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock ForecastsPTC Therapeutics Inc. is scheduled to release its earnings on
Nov 6, 2025,
after market closes.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
1 month ago
-9.89%
PTC Therapeutics shares are trading lower after th...
Unlock content with
Pro Subscription
2 months ago
+11.16%
PTC Therapeutics shares are trading higher after the company announced it has gained FDA approval for SEPHIENCE.
1 month ago · seekingalpha.com
PTC Therapeutics: HD Treatment Advancement Continues With Q4 2025 CatalystCompany is positioned for growth with SEPHIENCE, approved for PKU in the US and Europe, and pending decisions in Japan and Brazil. Votoplam (PTC518) for Huntington's Disease shows promising phase 2 re...
1 month ago · fool.com
PTCT Earnings Beat but Sales Drop 4%PTCT Earnings Beat but Sales Drop 4%